Skip to main content
2025 PharmSci 360 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Listen Now

Formulation and Delivery
Partner Presentation

Mitigating Viscosity Challenges in High-Concentration Protein Formulations with Hydroxypropyl β-Cyclodextrins (HPβCD)

Tuesday, November 11, 2025
3:00 PM - 4:00 PM CT
Location:360 Stage #1, Exhibit Hall

Sponsored By 
Formulation and Delivery Partner Presentation-Formulation

    Partner Presentation Speaker(s)

  • TAO PENG, PhD

    Senior BioPharma Research Manager
    Roquette Asia Pacific Pte Ltd
    Singapore, Singapore

Description: High-concentration protein formulations often face viscosity and stability-related challenges due to strong protein-protein interactions. This study shows that Hydroxypropyl-β-Cyclodextrin (HPβCD) effectively reduces viscosity in monoclonal antibody (mAb) formulations. For example, adding 5% HPβCD lowered the viscosity of a 180 mg/mL ipilimumab formulation from 39.5 cPs to 16.5 cPs. Mechanistic analyses indicate that HPβCD disrupts intermolecular hydrophobic attractions. As a well-established parenteral excipient, HPβCD offers a promising solution to improve injectability and stability in high-concentration protein formulations.

Learning Objectives:

  • Learn about the viscosity challenges in high-concentration monoclonal antibody formulations and the limitations of current excipients.
  • Explore the effectiveness and mechanism of action of Hydroxypropyl-β-Cyclodextrin in reducing viscosity
  • Understand the practical applications and potential impact of Hydroxypropyl-β-Cyclodextrin within the biopharmaceutical industry for improving manufacturability, drug delivery, and patient outcomes.